AR087919A1 - Heterociclos biciclicos como inhibidores de irak4 - Google Patents
Heterociclos biciclicos como inhibidores de irak4Info
- Publication number
- AR087919A1 AR087919A1 ARP120103448A ARP120103448A AR087919A1 AR 087919 A1 AR087919 A1 AR 087919A1 AR P120103448 A ARP120103448 A AR P120103448A AR P120103448 A ARP120103448 A AR P120103448A AR 087919 A1 AR087919 A1 AR 087919A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- independently selected
- occurrence
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
Formulaciones farmacéuticas que comprenden al menos uno de los compuestos inhibidores de quinasa de fórmula (1) junto con un vehículo, diluyente o excipiente aceptable desde el punto de vista farmacéutico. Reivindicación 1: Un compuesto de fórmula (1) y sus derivados, profármacos, N-óxidos, estereoisómeros, solvatos, sales aceptables desde el punto de vista farmacéutico y metabolitos biológicamente activos de los mismos; caracterizado porque, X se selecciona de O, S, y NH; A se selecciona de arilo o heteroarilo; R en cada aparición se selecciona independientemente de hidrógeno, ciano, halo, hidroxi, -NO₂, -NR³R⁴, alquilo opcionalmente sustituido, arilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido o heteroarilo opcionalmente sustituido; donde el sustituyente opcional, en cada aparición, se selecciona independientemente de halo, alquilo, haloalquilo, ciano, -NR⁵R⁶ o -COOR⁷; R¹ en cada aparición se selecciona independientemente de hidrógeno, halógeno, alquilo, arilo, heterocicloalquilo, heterocicloalquilalquilo, heteroarilo, Y-arilalquilo o Y-cicloalquilo; donde cicloalquilo, arilo, heterocicloalquilo, heterocicloalquilalquilo, heteroarilo y arilalquilo pueden ser sustituidos opcionalmente con hidroxi, alquilo, haloalquilo, ciano o halo; Y se selecciona de enlace directo, O, -C(O)- o NR⁷; R² en cada ocurrencia se seleccione independientemente de hidrógeno, carboxi, ciano, hidroxi, hidroxialquilo, alquilo, arilo, heteroarilo, -SO₂R⁵ u oxo; R³ y R⁴ se seleccionan independientemente de hidrógeno, hidroxialquilo, aminoalquilo, alquilo opcionalmente sustituido, heterociclilo opcionalmente sustituido, arilo opcionalmente sustituido; donde el sustituyente opcional, en cada aparición, se selecciona independientemente de halo, haloalquilo o -COOR⁷; R⁵ y R⁶ se seleccionan independientemente de hidrógeno, alquilo, COR⁷ o -COOR⁷; R⁷ en cada aparición se selecciona independientemente de hidrógeno o alquilo; y m, n y p se seleccionan de 1, 2 ó 3.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN3206CH2011 | 2011-09-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR087919A1 true AR087919A1 (es) | 2014-04-23 |
Family
ID=47178257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120103448A AR087919A1 (es) | 2011-09-19 | 2012-09-19 | Heterociclos biciclicos como inhibidores de irak4 |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR087919A1 (es) |
WO (1) | WO2013042137A1 (es) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2594742C2 (ru) | 2010-05-20 | 2016-08-20 | Эррэй Биофарма Инк. | Макроциклические соединения в качестве ингибиторов киназы trk |
WO2014058691A1 (en) * | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
WO2014180908A1 (en) * | 2013-05-08 | 2014-11-13 | Deutsches Krebsforschungszentrum | Acip/peptide-based inhibition of cancer cachexia |
US9168257B2 (en) | 2013-05-22 | 2015-10-27 | Children's Hospital Medical Center | Combination therapy for MDS |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
TWI667233B (zh) * | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
EP3092226B1 (en) | 2014-01-10 | 2019-03-13 | Aurigene Discovery Technologies Limited | Indazole compounds as irak4 inhibitors |
NZ760657A (en) * | 2014-01-13 | 2022-07-01 | Aurigene Discovery Tech Ltd | Bicyclic heterocyclyl derivatives as irak4 inhibitors |
WO2016022312A1 (en) * | 2014-08-05 | 2016-02-11 | Bristol-Myers Squibb Company | Heterocyclic kinase inhibitors |
AU2016293446A1 (en) * | 2015-07-15 | 2018-02-15 | Aurigene Discovery Technologies Limited | Substituted aza compounds as IRAK-4 inhibitors |
MX2018000577A (es) | 2015-07-16 | 2018-09-05 | Array Biopharma Inc | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la ret quinasa. |
EP3719016A1 (en) | 2015-08-04 | 2020-10-07 | Rigel Pharmaceuticals, Inc. | Benzazole compounds and methods for making and using the compounds |
CA3016364A1 (en) * | 2016-03-03 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | New 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs |
CN107417687A (zh) * | 2016-05-24 | 2017-12-01 | 中国科学院上海药物研究所 | 五元杂环并[3,4‑d]哒嗪酮类化合物、其制备方法、药物组合物及其应用 |
WO2017207340A1 (de) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
SG11201809470RA (en) * | 2016-06-01 | 2018-11-29 | Bayer Animal Health Gmbh | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals |
US11254667B2 (en) | 2016-08-17 | 2022-02-22 | Children's Hospital Medical Center | Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors |
US11542261B2 (en) | 2016-08-17 | 2023-01-03 | Children's Hospital Medical Center | Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors |
IL292977A (en) | 2016-09-09 | 2022-07-01 | Incyte Corp | Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy |
WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
US10280164B2 (en) | 2016-09-09 | 2019-05-07 | Incyte Corporation | Pyrazolopyridone compounds and uses thereof |
TW201811799A (zh) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
WO2018060072A1 (de) | 2016-09-29 | 2018-04-05 | Bayer Pharma Aktiengesellschaft | Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
WO2018060174A1 (de) | 2016-09-29 | 2018-04-05 | Bayer Pharma Aktiengesellschaft | Substituierte benzimidazole, pharmazeutische präparate diese enthaltend, sowie deren verwendung zur herstellung von arzneimitteln |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
US11547696B2 (en) | 2016-10-28 | 2023-01-10 | Children's Hospital Medical Center | Methods and compositions for treatment of myelodysplastic syndromes and/or acute myeloid leukemias |
JP6888101B2 (ja) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | RETキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピラジン化合物 |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
IL305150A (en) | 2017-03-31 | 2023-10-01 | Aurigene Oncology Ltd | Compounds and preparations for the treatment of hematological disorders |
US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
IL307995A (en) | 2017-09-22 | 2023-12-01 | Kymera Therapeutics Inc | Protein compounds and their uses |
TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
EP3704108B1 (en) | 2017-10-31 | 2024-04-24 | Curis, Inc. | Irak4 inhibitor in combination with a bcl-2 inhibitor for use in treating cancer |
US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
CN112105385A (zh) | 2017-12-26 | 2020-12-18 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
US11485743B2 (en) | 2018-01-12 | 2022-11-01 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
JP7060694B2 (ja) | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての置換ピロロ[2,3-d]ピリミジン化合物 |
CN111615514B (zh) | 2018-01-18 | 2022-10-11 | 奥瑞生物药品公司 | 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物 |
CN111630054B (zh) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物 |
US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
JP2021515033A (ja) | 2018-02-20 | 2021-06-17 | インサイト・コーポレイションIncyte Corporation | がんを治療するためのhpk1阻害剤としてのn−(フェニル)−2−(フェニル)ピリミジン−4−カルボキサミド誘導体及び関連化合物 |
PT3762368T (pt) | 2018-03-08 | 2022-05-06 | Incyte Corp | Compostos de aminopirazina diol como inibidores de pi3k-y |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
JP2022500383A (ja) | 2018-09-10 | 2022-01-04 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての縮合複素環式化合物 |
WO2020068729A1 (en) | 2018-09-25 | 2020-04-02 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators |
CN113423427A (zh) | 2018-11-30 | 2021-09-21 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
AU2020326703A1 (en) | 2019-08-06 | 2022-02-17 | Incyte Corporation | Solid forms of an HPK1 inhibitor |
EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
WO2021127190A1 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
US20230107927A1 (en) | 2020-02-28 | 2023-04-06 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
CA3194090A1 (en) | 2020-09-30 | 2022-04-07 | Takahiko Ito | Macrocyclic compound |
WO2022070289A1 (ja) | 2020-09-30 | 2022-04-07 | 旭化成ファーマ株式会社 | ピリミジン含有含窒素二環化合物 |
WO2023088435A1 (zh) * | 2021-11-19 | 2023-05-25 | 成都奥睿药业有限公司 | 三取代吡啶衍生物的制备及作为芳香烃受体调节物的应用 |
WO2024011116A2 (en) * | 2022-07-07 | 2024-01-11 | Dana-Farber Cancer Institute, Inc. | Potent and selective irreversible inhibitors of irak1 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003045385A1 (en) * | 2001-11-27 | 2003-06-05 | F. Hoffmann-La Roche Ag | Benzothiazole derivatives |
EP1628661A2 (en) * | 2003-06-05 | 2006-03-01 | Vertex Pharmaceuticals Incorporated | Modulators of vr1 receptor |
KR101099303B1 (ko) * | 2005-01-28 | 2011-12-26 | 주식회사 대웅제약 | 신규한 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물 |
-
2012
- 2012-09-14 WO PCT/IN2012/000615 patent/WO2013042137A1/en active Application Filing
- 2012-09-19 AR ARP120103448A patent/AR087919A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2013042137A1 (en) | 2013-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR087919A1 (es) | Heterociclos biciclicos como inhibidores de irak4 | |
ES2509820T3 (es) | Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer | |
AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
CU20080165A7 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
CO6251261A2 (es) | Derivados de 1- 82-amino-2-oxoalquil)-n(1h-indazol-5-il)pirrolidina-3-carboxamida | |
PE20160044A1 (es) | Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos | |
AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
CO6270259A2 (es) | Novedosos compuestos derivados de amina unidos con alcoxifenilo | |
DOP2010000046A (es) | Compuestos de biciclolactama sustituida | |
AR089774A1 (es) | Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
CO6160266A2 (es) | Derivado de oxopirazina y herbicida | |
AR062745A1 (es) | 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol como inhibidor de quinasa | |
AR066153A1 (es) | Derivados de piperidina / piperazina | |
AR067327A1 (es) | Derivados de piperidina / piperazina | |
ECSP11011365A (es) | Sales de adición de aminas que contienen grupos hidroxilo y/o carboxílicos con derivados de ácido aminonicotínico como inhibidores de dhodh | |
ES2662444T3 (es) | Derivado de piridina | |
AR078270A1 (es) | Inhibidores de jak (quinasas janus) | |
AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
ES2526902T3 (es) | Procesos de producción de inhibidores de la girasa y topoisomerasa IV | |
AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |